Diabetic Foot Ulcer - Drug Pipeline Landscape, 2023

Diabetic Foot Ulcer - Drug Pipeline Landscape, 2023

A diabetic foot ulcer is an open sore or wound that occurs in patients with diabetes and is commonly located on the bottom of the foot. It is one of the health complications caused due to uncontrolled diabetes, people with diabetes may also suffer from lower extremity arterial disease, which is a condition that leads to reduced blood flow. These problems make the feet vulnerable to skin sores, also known as ulcers. They usually occur under the big toes and surrounding areas.

Diabetic foot ulcers are mostly caused by poor blood circulation, hyperglycaemia, and nerve damage. Nerve damage reduces sensitivity to foot pain and results in painless wounds that can cause ulcers.

Diabetic foot ulcers are of two types, neuropathic ulcers, and vascular ulcers. The most visible sign of a serious foot ulcer is black tissue (called eschar) surrounding the ulcer. This forms because of an absence of healthy blood flow to the area around the ulcer.

Doctors most often diagnose diabetic foot ulcer by physical examination of toes, feet, and legs to check for an ulcer or blister present and blood tests, magnetic resonance imaging (MRI) and radiograph.

There are several treatment options for diabetic foot ulcer. The most common investigative treatments include antibiotics, antiplatelets, or anticlotting medications to treat the ulcer if the infection progresses even after preventive or anti pressure treatments. The primary treatment includes blood sugar control, removing dead tissue from the wound, dressings, and removing pressure from the wound through techniques such as total contact casting. Surgery in some cases may improve outcomes.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Diabetic Foot Ulcer treatment such as ON101, ENERGI-F703, APO-2, BB-101 and others. Key players involved in the development of therapies to treat Diabetic Foot Ulcer are Aposcience AG, Aurealis Therapeutics AG, Blue Blood Biotech Corp, Energenesis Biomedical Co Ltd, Oneness Biotech and others. One drug is under late-stage pre-registration, nine drugs are in Phase III clinical trials and 10+ drugs are in Phase II clinical trials and some other drugs are under Phase I, IND/CTA Filed, preclinical and discovery stages of development.

In December 2022, Oneness Biotech Co Ltd received a Malaysian patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on Fespixon cream (Research code: ON101).

Report Highlights

Global Insight Service's, Diabetic Foot Ulcer - Drug Pipeline Landscape, 2023 report provides an overview of the Diabetic Foot Ulcer pipeline drugs. This report covers detailed insights on Diabetic Foot Ulcer drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Diabetic Foot Ulcer pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.